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ABSTRACT 
As antibiotic resistance emerges stronger than ever, novel antimicrobial compounds are 
necessary to continue the infectious fight against disease and prevent millions of deaths by 
multidrug-resistant bacteria. One compound thought to be a natural source of antimicrobial 
activity is the chalcone. Abundant in fruits and vegetables, chalcones are versatile compounds 
that are easily synthesized via Claisen-Schmidt condensation and have demonstrated a wide-
range of biological activity. Previous studies have found that the addition of a free hydroxyl 
group to either the A or B ring of the chalcone skeleton may contribute to mild to moderate 
antimicrobial activity. Halogen substituents, such as bromine, chlorine, and fluorine, were also 
reported to aid in antibacterial activity. In this study, twenty chalcone compounds, fourteen of 
which had never been screened, were assessed for their antibacterial potential against two Gram-
negative and two Gram-positive strains of bacteria. This was assessed via Kirby-Bauer disk 
diffusion in which filter paper disks were impregnated with chalcone derivatives of varying 
concentrations, ranging from 1 µM to 1 mM, arranged on an agar plate swabbed with bacteria, 
and then incubated overnight. The potential for antimicrobial activity was quantified by 
measuring the zone of inhibition (ZOI) of the bacteria after disk diffusion. Similar to findings in 
prior studies, the results from this study suggest that electron donating groups (e.g. hydroxyl, 
ethoxy, and phenoxy groups) on the A ring may contribute to weak inhibition of both Gram-
positive and Gram-negative bacteria. Further studies must be conducted to determine a possible 
mechanism by which chalcones work on these microorganisms.   
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INTRODUCTION 
Natural Products 
Natural products can be defined and viewed differently depending on the scientific field 
or context. While natural products can be broadly defined as any substance produced by a living 
organism, the field of organic chemistry narrowly defines them as organic compounds produced 
as products or byproducts of metabolism, isolated from natural sources, and purified for 
industrial uses such as in medicine, for energy development, and for the production of consumer 
products such as food, health, and beauty products.1  In medicinal chemistry, the category of 
natural products is restricted even further to only include secondary metabolites.  
Secondary metabolites are organic compounds produced during metabolism which are 
not necessary for survival but may provide organisms with certain evolutionary advantages. 
Secondary metabolites play an important role in plants, serving as defense mechanisms against 
herbivores and other predators as well  as serving as signaling compounds to attract pollinators 
and other seed dispersing animals.2 Many years of natural selection and evolutionary processes 
have created compounds with high structural diversity, some exceeding the capabilities of 
synthetic organic chemists. These diverse compounds also possess many unique medicinal and 
biological properrties.1 While these compounds may have been synthesized over time to keep 
plants alive, they also have potential as drug scaffolds. It is these unique properties and complex 
structures that interest medicinal chemists, thus leading to the isolation, organic synthesis, and 
modification of these secondary metabolites.  
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Records from ancient Mesopotamia reveal that humans have been utilizing natural 
products for medicinal purposes as far back as 2600 BCE, when it was documented that healers 
used oils from the Cypress tree – from which compounds are still found useful today– to treat 
cough, colds, and inflammation.3  Additionally, Papaver somniferum, the original source of 
morphine and codeine, was used as early as 4000 BCE by the Sumerians, who nicknamed the 
plant, “hul gil” or joy-plant.4 The two compounds, morphine and codeine, likely evolved within 
the genus Papaver as a defensive mechanism against herbivores. In the 19th century, early 
organic chemists became interested in modifying the structure of morphine, taken from P. 
somniferum, to create a nonaddictive form of the drug. Instead, they acetylated morphine to 
produce heroin, which was actually more additive than its predecessor. Similarly, most modern 
medicinal chemists use natural products as basic scaffolds for drug design and employ synthetic 
changes to the base compounds to reduce side effects and increase therapeutic effect and overall 
bioavailability.  
In recent years, the pharmaceutical industry has seen a decline in the use of these 
compounds as drug developers focus more on synthetically derived drugs.5  However, with less 
than 10% of the world’s biodiversity currently being evaluated for biological properties, there are 
a multitude of compounds of great chemical diversity and unique biological and pharmaceutical 
functionality yet to be studied.3 
Classification  
Medicinal chemists often classify natural products into four main classes based broadly 
on their structure. These classes are terpenoids and steroids, alkaloids, fatty acid-derived 
substances and polyketides, and phenylpropanoids. Terpenoids are structurally diverse 
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compounds derived from 5-carbon monomers called isoprene. Alkaloids are compounds 
containing a basic amine group that are derived from amino acids.6 Fatty acid-derived substances 
and polyketides are synthesized from acyl precursors, or the building blocks of acetate and 
malonate. Phenylpropanoids are synthesized from the amino acids, phenylalanine and tyrosine.1 
Chalcones 
 Chalcones are a member of the polyketide class of natural products. They are small 
compounds composed of two aromatic rings joined by a three carbon α, β-unsaturated carbonyl 
system.7 
 
Figure 1. 1,3-Diphenylprop-2-en-1-one. Figure taken from Das, et al. (2018)  
It is the conjugation of the double bond with the carbonyl group of the chalcone that is thought to 
contribute to its biological activity, as removal of this conjugated system makes them inactive. 
Chalcones are found abundantly in edible plants and serve as intermediates in the flavonoid 
metabolic pathway.8 
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 Chalcone Biosynthesis and Modification 
 
Figure 2. Reaction Scheme for the Synthesis of Chalcones via Claisen-Schmidt Condensation. Figure taken from Durairaj M., et 
al. (2018)9 
 In the laboratory setting, chalcones are synthesized by Classen-Smith Condensation 
(Figure 2). They can be modified by reacting substituted acetophenones and benzaldehydes to 
produce novel chalcone derivatives with substitutions to either the A or B ring.10 By making 
substitutions to either ring, chemists hope to alter the biological properties to discover a novel 
use of the compound or improve a known property through modification of a base structure.  
 Biological and Pharmaceutical Properties 
 Chalcones have been studied for an extensive range of biological and pharmaceutical 
properties. Researchers have evaluated chalcones and their analogues as anti-cancer, 
antiprotozoal, anti-HIV, and antioxidant agents as well as tested them for anti-malarial, 
antimicrobial, and anti-inflammatory properties.8 In addition to their versatility, clinical studies 
have also demonstrated excellent bioavailability and maximum tolerance in vivo. In fact, there 
are currently several drugs on the market or in clinical trials that contain the chalcone skeleton in 
their structures. For instance, metochalcone was approved as a choleretic drug, used to treat liver 
and gallbladder disease, and sofalcone was approved as an anti-ulcer medication.11 
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Antimicrobials 
 Antibiotics  
Antibiotics are drugs used to fight bacterial infections. They are designed to selectively 
target bacterial cells without affecting animal cells.12 This is accomplished by taking into 
consideration the differences between the two cell types and targeting specific properties of 
bacterial cells. Moreover, most species of bacteria fall into one of two groups based on a staining 
technique, which reveals unique characteristics about the cell. Gram-positive cells have a thick 
cell wall (20-40 nm) and stain purple. Gram-negative cells have a thinner cell wall (2-7 units) 
and an outer membrane composed of lipopolysaccharides; these bacteria stain pink. Furthermore, 
there are some bacteria called mycobacteria that are impermeable to gram staining due to the 
presence of mycolic acid in their cell walls. These bacteria can appear as either Gram-positive or 
Gram-negative because they share characteristics of both groups.14 Due to these structural 
differences, some classes of antibiotics work to treat Gram-negative or Gram-positive infections 
more effectively due to their mechanism of action. 
Mechanisms of Action 
Most antibiotics can be grouped into one of five main mechanisms of action (MOA).12 
The first antibiotic mechanism works by inhibiting the cell’s metabolism. These agents are 
termed antimetabolites. The primary mechanism by which this is accomplished is by inhibiting 
an enzyme-catalyzed reaction which is present in bacterial cells but not in mammalian cells. This 
is the mechanism of action of the sulphonamide class of antibiotics. They work as competitive 
enzyme inhibitors of the bacterial enzyme, dihydropteroate synthetase, resulting in the disruption 
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of tetrahydrofolate biosynthesis in the cell. Tetrahydrofolate is an enzyme cofactor involves in 
pyrimidine nucleic acid base synthesis. Mammals receive folic acid, the precursor to 
tetrahydrofolate, in their diet; therefore, they do not possess this enzyme.13 By blocking 
production of these nucleic acids, DNA synthesis is interrupted, and the bacterial cells can no 
longer grow and multiply.  
Secondly, antibiotics can work by inhibiting bacterial cell wall synthesis causing cell 
lysis and death.12 Penicillins, cephalosporins, and glycopeptides such as vancomycin act by this 
MOA. Penicillins work by inhibiting the enzyme, transpeptidase, which is responsible for the 
final cross-linking reaction in bacterial cell wall synthesis. Without the interlinking of the sugar 
backbone, the framework for the bacteria’s cell wall becomes compromised, making it more 
fragile and susceptible to swelling and eventual cell lysis.  
Other antibiotics work by interacting with the plasma membrane, thereby affecting 
membrane permeability and resulting in eventual cell death. Both polymyxins and tyrothricin 
work in this manner. Polymyxin B, a commonly used polypeptide antibiotic, works by acting 
selectively on the lipopolysaccharide outer membrane of Gram-negative bacteria. It works to 
displace the calcium and magnesium bridges that stabilize the lipopolysaccharides causing an 
uncontrolled leakage of small molecules like nucleosides out of the cell.15 The mechanism of 
selectivity by which this antibiotic works is not fully understood.  
Antibiotics can also work to disrupt protein synthesis and halt the production of essential 
proteins and enzymes.12 Agents working in this way include the rifamycins, aminoglycosides, 
tetracyclines, and chloramphenicol. Rifamycins work by inhibiting RNA synthesis in bacteria by 
blocking the prokaryotic DNA-dependent RNA polymerase. Rifamycins have a 100-10,000-fold 
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greater affinity for prokaryotic RNA polymerase than eukaryotic enzyme.16 Aminoglycosides, 
like streptomycin, neomycin, and tobramycin, work effectively on Gram-negative organisms.10 
In slightly alkaline conditions, they carry a positive charge which interacts with various 
negatively charged groups on the outer surface of the cell membrane allowing more ready 
absorption into the bacterial cell. Once in the cell, they bind to specific bacterial proteins in the 
30S ribosomal subunit and restrict movement of the ribosome along mRNA, making it 
impossible to read the code and synthesis proteins. Tetracyclines also bind to bacterial ribosomes 
and prevent transcriptions, but they are more broad-spectrum allowing them to kill both Gram-
negative and Gram-positive cells. Chloramphenicol works similarly to tetracyclines by diffusing 
through the bacteria cell wall and binding to the bacterial 50S ribosomal subunit, thus interfering 
with peptide elongation and blocking protein synthesis.17 
Lastly, antibiotics can work to inhibit nucleic acid replication and transcription, thereby 
preventing cell division or halting the production of essential proteins.12 Both nalidixic acid and 
proflavine work by this MOA. Nalidixic acid was the first agent discovered in the class later 
known as the quinolones and fluroquinolones. They inhibit the replication and transcription of 
bacterial DNA by stabilizing the interaction between topoisomerases and DNA resulting in an 
enzyme with no activity. Proflavine works by intercalating DNA, thereby distorting the structure 
such that it can no longer by replicated. This disruption of DNA synthesis prevents bacterial 
reproduction.18 
Antibiotic Resistance 
Antibiotic resistance occurs when bacteria develop the ability to survive exposure to 
antibiotics.19 The mechanism by which this resistance develops is either by genetic mutation of 
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the bacterial DNA which in turn provides the bacteria an evolutionary advantage or by 
acquisition of an antibiotic resistance gene from other bacteria stains via horizontal gene transfer. 
As these antibiotic resistant bacteria grow and multiply within the host, they remain unaffected 
by the antibiotics used to kill them or stop their growth. Infections caused by antibiotic resistant 
bacteria can be very difficult to treat, often requiring costly and toxic alternatives to traditional 
antibiotics. Unfortunately, antibiotic resistance has been an increasingly more urgent issue over 
the past few decades. In 2014, the prime minister of United Kingdom commissioned a “Review 
on Antimicrobial Resistance,” the purpose of which was to take a look at the global issue of 
rising antimicrobial resistance and proposed reasonable plans to tackle the issue in the long 
term.20 In this report, they predicted that by 2050, 10 million people will die each year due to 
multidrug resistant pathogens. The global cost due to these infections was projected to reach 100 
trillion US dollars, if no action is taken. Moreover, the rapid growth of antibiotic resistance 
threatens advances in modern healthcare.19 The advent of antibiotics has allowed many 
procedures that typically have a high risk of infection to become common place. However, as 
effective antibiotics become unavailable, healthcare providers will no longer be able to safely 
perform common surgeries, like hip replacements, or administer chemotherapeutics, which lower 
the recipient’s immune system. 
This steady increase in antibiotic resistance can be attributed to two main factors, (1) the 
prescription of antibiotics to treat infections of a nonbacterial nature, such as viral infections, and 
(2) lack of patient compliance.21 For instance, when patients do not complete their full course of 
antibiotic therapy because they begin to feel better and feel they no longer need it, the patient 
becomes more susceptible to the growth of antibiotic-resistant bacteria. This occurs because 
patients take a sublethal dose, and as a result, do not completely kill off the infectious bacteria. 
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While nationwide efforts promoting better drug adherence and more effective diagnostic 
tools can help slow the development of antibiotic resistance, it cannot be stopped.22 As bacteria 
evolves, growth in antibiotic resistance is inevitable. There will always be a need for new 
antibiotics to keep up with resistant bacteria. However, despite the need for new therapies, the 
antibiotic drug pipeline is currently scarcely populated.3 In fact, the number of major 
pharmaceutical companies invested in the production new antibiotic therapies has decreased 
from 18 in 1990 to only 4 in 2013.20 
Antimicrobial Properties of Chalcone Derivatives 
Historically, natural products have been pivotal in the discovery and development of 
antibiotics.5 The first modern antibiotic, penicillin, was discovered because it is naturally 
synthesized by Penicillium mold. Furthermore, of the nine classes of antibiotics, six are based on 
natural products, while only three classes (sulfonamides, fluoroquinolones, and oxazolidinones) 
rely entirely on synthetic chemistry.21 As antibiotic resistance continues to emerge as a threat to 
global health, researchers are beginning to gravitate back to where it all began – finding natural 
products with antibiotic activity.7 Among the many other pharmacological activities of these 
molecules, the antimicrobial effects of chalcone derivatives have been a hot topic of interest 
amongst many medicinal chemists. 
In previous studies, researchers have found that the bactericidal effects of chalcone 
derivatives may be linked to the tendency of the α,β-unsaturated ketone of the chalcone to react 
with a nucleophilic group, like a thiol group in a protein, and undergo conjugated addition. In 
addition to proposing a mechanism for their activity, researchers are also interested in better 
understanding the structure-activity relationship (SAR) between chalcones and their antibacterial 
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properties. The purpose of SAR analysis is to determine possible pharmacophores, or chemical 
structures responsible for evoking certain biological effects. Many studies have found that 
electron-releasing groups, such as methoxy and hydroxy groups, may contribute to antibacterial 
activity, as chalcones with these type of additions have demonstrated mild to moderate inhibition 
in vivo.23, 24, 25, 26 Compounds containing halogen substituents (e.g. chlorine, bromine, fluorine) 
have also shown potential as possible antimicrobial agents.27, 28, 29, 30   The purpose of this thesis is 
two-fold: (i) evaluate an existing chalcone library for antimicrobial activity and (ii) analyze 
findings from the study to determine what type of substituents may contribute to bacterial 
inhibition.
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METHODS 
Kirby-Bauer Disk Diffusion 
 
Figure 3. Full library of chalcone compounds synthesized by Tucker, et al. (2017) 
Chalcones were obtained from the Krzysiak lab at Bellarmine University (Louisville, 
KY) (Figure 3). They were synthesized by Claisen-Schmidt Condensation10 and stored in glass 
vials at room temperature. GE Healthcare Whatman™ Antibiotic Assay Discs were purchased 
from Fisher Scientific (Hampton, NH). Chalcones were diluted in dimethyl sulfoxide (DMSO) to 
four different doses (1 mM, 100 µM, 10 µM, 1 µM) for use in disk diffusion. Disks were 
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prepared by applying 25 µL of the diluted chalcone/DMSO solution to an individual 6 mm blank 
disc. The solution was allowed to soak into the disk for 15-20 minutes prior to placement to 
allow for complete absorption. DMSO (25 uL) was applied to blank discs for use as a negative 
control. Ciprofloxacin discs were used as a positive control for all four bacterial cultures.  
Four MicroKwik cultures ® (Streptococcus pneumoniae, Salmonella enteritidis, Bacillus 
subtilis, and Escherichia coli) were purchased from Carolina Biological Supply (Burlington, NC) 
and reactivated according to the manufacturer’s instructions. After initial incubation, each 
bacterial culture was then initiated via heavy inoculum and grown at the optimal growth 
temperature on the suggested growth media for 24-48 hours (Table 1). These plates were used as 
stock plates; colonies were taken from them as needed for broth cultures.  
Table 1. Bacterial Growth Conditions 
Bacterial Strain Growth Medium Optical Growth 
Temperature (°C) 
Streptococcus 
pneumoniae 
Tryptic Soy Agar with 
5% Sheep Blood 
37 
Salmonella enteritidis LB Agar 37 
Bacillus subtilis LB Agar 30 
Escherichia coli LB Agar 37 
Two to three colonies were plucked from the stock plate via a sterile inoculation loop and 
transferred into LB broth; the LB broth was then incubated for 24-72 hours at the optimal growth 
temperature. The optical density of the broth was measured at 600 nm, and the broth cultures 
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were diluted to 0.7 before being plated. This method of standardizing the turbidity was used as 
opposed to the McFarland standard protocol.31 
Each chalcone was tested against all four organisms, and every assay was run in 
triplicate. Plates were inoculated using a sterile cotton swab. The cotton swab was dipped in the 
broth culture, and the surface of each plate was swabbed over the entire surface three times – 
with a 60-degree rotation between each to ensure proper distribution. Disks were applied 
according to the diagram below. 
 
Figure 4. Disk Placement for Disk Diffusion (Anterior view). Graphic created by author. 
The plates were incubated at optimal growth temperature and stored upside down to 
prevent collection of water droplets. After 24-36 hours, plates were visually assessed, and zones 
of inhibition were measured for each disk. 
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RESULTS  
To determine if chalcone derivatives synthesized at Bellarmine University have 
antibacterial activity, each compound was screened via a Kirby-Bauer disk diffusion assay. This 
is a method used to quantify bacterial inhibition due to the presence of a specific compound. At 
the start of this study, the full Tucker, et al. library was reviewed for antimicrobial properties 
using the SciFinder database (Figure 3). This database allows users to search for literature related 
to a specific chemical structure and certain biological activities. The selected chalcones were 
chosen based on available stock and the number of “hits” in the database relating to how many 
studies looked at the same structure in the same context. It is important to note that chalcone 
1A1B had the greatest number of hits because it is typically cited as a basic scaffold structure in 
most studies looking at chalcone derivative activity. In this case, the number of hits on the 
database does not correlate directly with increased biological activity, it simply correlates with 
use of the compound in prior studies. Chalcones with the fewest hits in the literature were 
selected for this study. Out of the chalcones available for testing, twenty were chosen for disk 
diffusion (Table 2). 
TABLE 2. Results from SciFinder Literature Survey – Chalcones chosen for antibacterial 
screening.  
Previous publication(s) according to 
SciFinder database 
Chalcones 
Not previously studied (No “hits” on 
SciFinder) 
2A1B, 3A2B, 5A2B, 4A3B, 5A3B, 
2A4B,5A4B, 2A5B, 3A5B, 3A’5B, 4A5B, 
3A6B, 3A’6B, 5A6B 
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Not assessed against the same organisms  5A1B, 1A3B 
Structure only assessed in one prior study 
using similar organisms 
4A2B 23, 1A4B24, 4A4B 24, 2A6B 25 
 
Each chalcone that was identified to have potential antimicrobial activity was tested 
against four different bacterial strains (Streptococcus pneumoniae, Salmonella enteritidis, 
Bacillus subtilis, and Escherichia coli) using the Kirby Bauer disk diffusion method. In order to 
quantify antibacterial activity, zones of inhibition were measured for each chalcone compound 
and the controls for each plate. Zone of inhibition was measured by taking the diameter of the 
circular area around the disc of interest in which the bacteria did not grow. Since the discs used 
in the assay were 6 mm in diameter, ZOIs greater than 6 mm demonstrated some antimicrobial 
activity. Appendix A shows the raw data collected from the disk diffusion assay. Photographs of 
each plate can be found in Appendix B. The results indicate that none of the chalcone derivatives 
tested showed significant inhibition of bacterial growth across any of the four strains they were 
tested against. Some compounds, however, did show weak inhibition of growth against specific 
bacterial strains. These results are summarized in Table 2.  
TABLE 3. Antibacterial activity of chalcones* against three bacterial strains.  
Chalcone 
ID and 
structure 
Test Strain Strength effective 
Zone of 
inhibition 
(mm) 
Substituent properties 
Gram-Positive 
3A2B S. pneumoniae 10 µM 6.5 mm  
A Ring: Electron-donating 
B Ring: Electron-donating 
4A2B** S. pneumoniae 10 µM 6.5 mm  
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B. subtilis 1 mM 
9.25 mm 
  
A Ring: Electron-donating 
group   
B Ring: Electron-
withdrawing group 
5A3B S. pneumoniae 1 µM 6.1 mm 
A Ring: Electron-donating 
group 
B Ring: Hydrophobic 
Gram-Negative 
5A2B S. enteritidis 
1 µM 
7.5 
mm             
A Ring: Electron-donating 
group 
B Ring: Hydrophobic 
10 µM 7 mm 
100 µM 8 mm 
1 mM 9 mm 
1A4B** S. enteritidis 1 µM 6.75 mm 
A Ring: Electron-donating 
group 
B Ring: N/A 
2A6B** S. enteritidis 
1 µM 7 mm  
A Ring: Hydrophobic 
B Ring: Hydrophobic 
1 µM 7 mm 
10 µM 7.75 mm 
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Gram Positive Strains 
    
Figure 5. Gram-positive bacteria growing on agar plates with chalcones showing mild bacterial inhibition. Photos taken by 
author. 
 In the Kirby-Bauer disk diffusion assay, the selected chalcones were evaluated for 
antimicrobial activity against two strains of gram-positive bacteria, S. pneumoniae and B. 
subtilis. The results of the assay suggest that chalcones 3A2B, 4A2B, and 5A3B may have 
potential as antimicrobial agents effective against gram-positive bacterial strains. In terms of 
structural similarity, all three compounds have electron-donating substituents on the A ring, 
whereas additions to the B ring vary among the compounds. 
Gram Negative Strains 
   
Figure 6. Gram-negative bacteria growing on agar plates with chalcones showing mild bacterial inhibition. Photos taken by 
author.  
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The selected chalcones were also evaluated against two gram-negative strains of bacteria, 
S. enteritidis and E. coli. None of the selected chalcones showed activity against E. coli. 
Chalcones 5A2B, 1A4B, and 2A6B demonstrated weak inhibition of S. enteritidis. Among the 
three compounds, two have electron-donating additions to the A ring, while the other had a 
hydrophobic addition. As for additions to the B ring, both compounds with substituents to the B 
ring had hydrophobic substituents. In summary, the results for the gram-negative strains are 
generally inconclusive. However, when results from all four strains are considered, it seems that 
electron-donating additions to the A ring may be important for activity against both gram-
negative and gram-positive strains as five out of six active compounds possess this type of 
addition. 
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DISCUSSION 
 In this study, twenty chalcone derivatives were evaluated for antibiotic potential via 
Kirby Bauer disk diffusion. The results of the assay were quantified by measuring the zone of 
inhibition for each compound as well as positive and negative controls. Chalcone derivatives 
showing ZOIs greater than 6 mm demonstrated potential as antimicrobial agents. Out of the six 
compounds that were found to be active in this study, three of the chalcones (4A2B, 1A4B, and 
2A6B) have been evaluated in prior studies assessing antimicrobial activity (Table 1). 
Chalcone 4A2B was assessed by Gasha, et al. (1972) in a study looking at antimicrobial 
activity of a specific chalcone library.32 Instead of evaluating antimicrobial potential by disk 
diffusion, they found the minimum inhibitory concentration (MIC) of each compound they 
tested. MIC is the minimum concentration of a compound needed to inhibit viable growth of an 
organism. The lower the MIC, the more effective the compound is at inhibiting growth. The MIC 
of 4A2B was greater than 12.5 µg/mL for all ten strains it was tested against, including B. 
subtilis and E. coli. When compared to other compounds in the study, chalcone 4A2B exhibited 
weak inhibition of bacterial and fungal growth. In the study conducted in this thesis, chalcone 
4A2B only exhibited weak inhibition of the gram-positive strains of bacteria with no inhibition 
of E. coli.  
A study conducted by Kalyanasundaram, et al. (2014) tested chalcone 1A4B, referred to 
in the study as “entry #1,” against B. subtilis and E. coli via Kirby Bauer disk diffusion. They 
found that the compound weakly inhibited the growth of the B. subtilis with a zone of inhibition 
of 8 mm, while no inhibition was seen against the E. coli.33 In this study, however, chalcone 
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1A4B had the opposite effect. The compound was ineffective against B. subtilis, a gram-positive 
strain, and instead weakly inhibited growth of S. enteritidis, a gram-negative strain of bacteria. 
Lastly, Budhiraja, et al. (2012) assessed 2A6B for antimicrobial properties and found that 
the compound was not effective against any of the organisms used, including B. subtilis and E. 
coli.34 2A6B showed a MIC of 125 µg/mL against both strains demonstrating very weak 
inhibition of growth. In this study, 2A6B weakly inhibited growth of S. enteritidis in two out of 
three trials. It is important to note that none of these compounds were tested against S. 
pneumoniae or S. enteritidis in prior studies. 
Chalcone 4A4B was also previous assessed in the study by Kalyanasundaram, et al. 
(2014). They found 4A4B to be active against E. coli with a zone of inhibition of 8 mm, whereas 
in this study, the compound was not active against any bacterial strain, including E. coli.33 Based 
on the results of this assay, there may have been an experimental error in the growth of the E. 
coli culture because none of the chalcone compounds that were active against E. coli in prior 
studies were active in this study. Moreover, it was the only strain whose growth was not 
inhibited by any of the compounds tested. This could be attributed to potential contamination of 
the culture, leading to growth of other bacterial strain(s) that were only susceptible to 
ciprofloxacin, the broad-spectrum antibiotic utilized as the positive control.  
Among the six compounds with antibacterial potential, five had electron-donating 
substituents to the A ring, whereas substituents to the B ring varied among the group. This 
suggests that antibacterial activity may be associated with electron-donating additions to the A 
ring. This finding has been supported by other studies. For instance, Silva et al. (2013) did a 
similar study looking at the effect of certain chalcone derivatives on bacterial growth. They 
Frazier 27 
found that the best activity was achieved when a hydroxyl group, an electron-donating group, 
was added in the ortho-position to the A-ring of the compound.26 The absence of a hydroxyl 
group to the A-ring resulted in no antibacterial activity. 
There has been debate regarding whether the position of the electron-donating 
substituents, A versus B-ring, matters when it comes to antibacterial activity. Many studies have 
found that electron-donating substituents to the B ring show better activity. In a review looking 
at anti-infective and anti-inflammatory properties of chalcones, Nowakowska (2007) noted that 
analogues of licochalcone A (Figure 5), a chalcone isolated from licorice root, were found to be 
inactive without the free hydroxyl group, an electron-donating group, in the 4’-position of ring 
B.7 Removal of the free-hydroxyl from the A-ring, on the other hand, had no effect on the 
activity. Moreover, a study completed by Hasan, et al looked at a series of six chalcone 
derivatives and evaluated their activity against both bacteria and fungi.35 They found that 
electron-donating groups, specifically methoxy and hydroxy groups, on the B ring were most 
effective at inhibiting bacterial growth. They did not, however, test the same substituents to the 
A ring.  
 
Figure 7.. Licochalcone A - a compound isolated from Glycyrrhiza inflata, or licorice root that has shown potent antibacterial 
activity against Bacillus subtilis,Staphylococcus aureus and Micrococcus luteus. Figure taken from Nowakowska. (2007) 
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Prior evidence also supports the addition of hydrophobic substituents to the chalcone 
scaffold to increase antibacterial activity. Chalcone 2A6B possesses two hydrophobic 
substituents, one to the A-ring and one to the B-ring. In her review, Nowakowska (2007) also 
cited that removal of the lipophilic prenyl group of licochalcone A analogues results in total loss 
of activity in these compounds.7 Therefore, hydrophobicity, also referred to as lipophilicity, 
plays an essential role in the antibacterial effect of lipochalcone A analogues. 
While no new trends in data or unique SAR were noted in this study, the results of this 
study contribute to the growing knowledge of what we currently know about chalcones and their 
antibacterial activity. This study serves to further show that electron-donating substituents, like 
methoxy and hydroxy groups, play an important role in antibacterial activity. Additionally, this 
study assessed fourteen new structures as possible antibacterial agents and found two new 
compounds with antibiotic potential. Modification of these compounds in future studies may 
allow for synthesis of structures with even greater antibiotic activity. This study was limited 
because it relied on a previously synthesized library of compounds and it only evaluated 
chalcones against four common strains of bacteria. Further research could certainly be conducted 
evaluating more potentially harmful bacterial strains, such as multidrug resistant bacteria or 
mycobacterium. Overall, this study provides further evidence that chalcones show potential as 
antibacterial agents. In addition to their versatility, chalcones are also easily synthesized and 
cost-effective, making them attractive as potential drug scaffolds. Furthermore, six out of nine 
classes of antibiotics currently used today come from natural products. Considering the amount 
of biodiversity not yet evaluated for medicinal purposes, there are many compounds yet to be 
assessed for use in antibacterial therapy. In a world of growing antibiotic resistance, natural 
products, like chalcones, should be considered as possible agents in the fight against disease. 
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APPENDIX A – ZONE OF INHIBITION MEASUREMENTS 
TABLE 4. Zone of Inhibition Measurements for S. pneumoniae 
Chalcone Strength/Control Zone of Inhibition* (mm) –Two diameter measurements 
were taken for each disk, and the two measurements 
were averaged. 
Plate 1 
average 
Plate 2 
average  
Plate 3 
average  
Average 
across all 
plates 
2A1B Positive 29.75 29 28.75 29.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A1B 
 
Positive 31 28.5 29.5 29.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A2B Positive 30.75 29.75 29.75 30.08 
Negative - - - - 
1 µM - - - - 
10 µM - 6.5 - 6.17 
100 µM - - - - 
1 mM - - - - 
4A2B Positive 31.75 30.75 30 30.83 
Negative - - - - 
1 µM - - - - 
10 µM 6.5 - - 6.17 
100 µM - - - - 
1 mM - - - - 
5A2B Positive 32 31.25 29.5 30.92 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
1A3B Positive 30.75 31 29.5 30.42 
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Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A3B Positive 31 30.25 30 30.41 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A3B Positive 30.25 30 31.75 30.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
1A4B Positive 30.5 30 30.25 30.75 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A4B Positive 30 30.75 39.5 30.08 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A4B Positive 29.5 27 28.5 28.33 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A4B Positive 28.5 30 30 29.5 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
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100 µM - - - - 
1 mM - - - - 
2A5B Positive 30 30 31 30.33 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’5B Positive 31 28 29 29.33 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A5B Positive 30.5 28 29 29.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A5B Positive ND 29 29.5 29.25 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A6B Positive 30 28.5 27.5 28.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’6B Positive 27.5 29.5 29.6 28.33 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A6B Positive 26 30 29 28.33 
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Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A6B Positive 30 29 28 29 
Negative 6.25 - - 6.08 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
*The dash (-) represents 6 mm, or no inhibition. ND means “not determined;” this designation 
was used for ZOI that were disrupted by either other ZOI or cracks in the agar. 
 
TABLE 5. Zone of Inhibition Measurements for S. enteritidis 
Chalcone Strength/Control Zone of Inhibition* (mm) – Each ZOI measurement was 
taken twice and the two measurements were averaged. 
Plate 1 
average 
Plate 2 
average  
Plate 3 
average  
Average 
across all 
plates 
2A1B Positive 41 41 42 41.33 
Negative ND 8 ND 8 
1 µM - 7 - 6.33 
10 µM - - - - 
100 µM - - - - 
1 mM ND ND ND ND 
5A1B 
 
Positive 42.25 41.5 43.5 42.42 
Negative - ND - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM  - - - 
3A2B Positive 42 43.5 43 42.83 
Negative - ND - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM ND - ND - 
4A2B Positive 43 40.5 3.9 29.13 
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Negative ND ND ND ND 
1 µM - - - - 
10 µM - - - - 
100 µM - - ND - 
1 mM ND ND ND ND 
5A2B Positive 39.5 40 38 39.17 
Negative - - - - 
1 µM - - 7.5 6.5 
10 µM - - 7 6.33 
100 µM - - 8 6.67 
1 mM - - 9 7 
1A3B Positive 37.5 39 40.5 39 
Negative ND ND ND ND 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A3B Positive 39 38.5 39.5 39 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A3B Positive 40 39.5 39.5 39.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM ND ND - - 
1A4B Positive 38.5 41.5 40 40 
Negative - - 7 6.33 
1 µM - 6.75 7 6.58 
10 µM - - 7 6.33 
100 µM - - 7 6.33 
1 mM - ND 7 6.5 
2A4B Positive 41.5 40.5 39.5 40.5 
Negative - - 7 6.33 
1 µM - - 7 6.33 
10 µM - - 7 6.33 
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100 µM - - 7 6.33 
1 mM - ND 7 6.5 
4A4B Positive 39 38.5 43.5 40.33 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM ND - ND - 
5A4B Positive 42.5 43.5 40.5 42.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM ND ND ND ND 
2A5B Positive 39.5 36.5 37.5 37.83 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - ND - - 
3A’5B Positive 38.5 35 35 36.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A5B Positive 35 3.- 38 25.53 
Negative - - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A5B Positive 35 3.- 36.5 25.03 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A6B Positive 39 3.75 36.5 26.42 
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Negative - ND - - 
1 µM 7 - 7 6.67 
10 µM - - 7.75 6.58 
100 µM - - - - 
1 mM - - - - 
3A’6B Positive 37 38 38.5 37.83 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A6B Positive 36.5 38 37 37.17 
Negative - ND - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A6B Positive 40 38.25 39 39.08 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
*The dash (-) represents 6 mm, or no inhibition. ND means “not determined;” this designation 
was used for ZOI that were disrupted by either other ZOI or cracks in the agar. 
 
TABLE 6. Zone of Inhibition Measurements for B. subtilis 
Chalcone Strength/Control Zone of Inhibition* (mm) – Each ZOI measurement was 
taken twice and the two measurements were averaged. 
Plate 1 
average 
Plate 2 
average  
Plate 3 
average  
Average 
across all 
plates 
2A1B Positive 35 32.5 32.25 33.25 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A1B Positive 36.75 34.5 32 34.42 
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 Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A2B Positive 35.75 37 32.75 35.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A2B Positive 36 33.5 32 33.83 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - 9.25 - 7.08 
5A2B Positive 36 32.5 34.25 34.25 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
1A3B Positive 34 33 34 33.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A3B Positive 35.75 34.5 33.5 34.58 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A3B Positive 36 34.5 33 34.5 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
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100 µM - - - - 
1 mM - - - - 
1A4B Positive 34.5 34.5 33.5 34.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A4B Positive 34.5 33.5 36.5 34.83 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A4B Positive 35.25 33.75 31.5 33.5 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A4B Positive 33.25 34 31.5 32.92 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A5B Positive 34.75 32.5 31.5 32.92 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’5B Positive 35.25 33.5 32.5 33.75 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A5B Positive 37 34.5 33.5 35 
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Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A5B Positive 34.25 34 33 33.75 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A6B Positive 36 32.5 31.5 33.33 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’6B Positive 34 32.5 33 33.17 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A6B Positive 34 33.75 31 32.92 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A6B Positive 35 33.5 32.5 33.67 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
*The dash (-) represents 6 mm, or no inhibition. ND means “not determined;” this designation 
was used for ZOI that were disrupted by either other ZOI or cracks in the agar. 
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TABLE 7. Zone of Inhibition Measurements for E. coli 
Chalcone Strength/Control Zone of Inhibition* (mm) – Each ZOI measurement was 
taken twice and the two measurements were averaged. 
Plate 1 
average 
Plate 2 
average  
Plate 3 
average  
Average 
across all 
plates 
2A1B Positive 43.5 44 39.5 42.33 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A1B 
 
Positive 42 43.5 37 40.83 
Negative - ND ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A2B Positive 42.25 42.5 40.5 41.75 
Negative ND - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A2B Positive 42 42.75 40.5 41.75 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A2B Positive 43.75 42.75 42 42.83 
Negative ND ND ND ND 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
1A3B Positive 44.5 43 40 42.5 
Negative - ND - - 
1 µM - - - - 
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10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A3B Positive 45.75 43.75 39.5 43 
Negative - - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A3B Positive 44.75 44.5 40 43.08 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
1A4B Positive 43.25 40 40.5 41.25 
Negative ND - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A4B Positive 43.75 40 3-.5 40.08 
Negative ND ND ND ND 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A4B Positive 41.5 41 39 40.5 
Negative - ND - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A4B Positive 43.5 43.75 39.5 42.25 
Negative - - - - 
1 µM - ND - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
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2A5B Positive 40.5 43.5 38.5 40.83 
Negative ND - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’5B Positive 43.5 4-.5 39.25 43.08 
Negative - - ND - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A5B Positive 42.5 42.5 39.75 41.58 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
4A5B Positive 42.5 40.75 40 41.08 
Negative ND - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
2A6B Positive 43.5 43 39.5 42 
Negative - ND - - 
1 µM - - ND - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A’6B Positive 43.5 41.5 39.5 41.5 
Negative - ND - - 
1 µM ND - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
3A6B Positive 42 40.5 40 40.83 
Negative - - - - 
1 µM ND - - - 
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10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
5A6B Positive 40 40.25 39 39.75 
Negative - - - - 
1 µM - - - - 
10 µM - - - - 
100 µM - - - - 
1 mM - - - - 
*The dash (-) represents 6 mm, or no inhibition. ND means “not determined;” this designation 
was used for ZOI that were disrupted by either other ZOI or cracks in the agar. 
 
APPENDIX B – PHOTOS OF AGAR PLATES POST-INCUBATION SHOWING ZONE 
OF INHIBITION 
TABLE 8. Post-chalcone diffusion photographs of S. pneumoniae grown on Tryptic Soy 
Agar with 5% Sheep Blood after 24-36-hour Incubation at 37° C  
CHALCONE PLATE 1 PLATE 2 PLATE 3 
2A1B 
   
5A1B 
   
Frazier 48 
3A2B 
   
4A2B 
  
 
5A2B 
 
  
1A3B 
  
 
4A3B 
  
 
Frazier 49 
5A3B 
 
 
 
1A4B 
   
2A4B 
 
  
4A4B 
 
  
5A4B 
  
 
Frazier 50 
2A5B 
  
 
 
 
3A’5B 
   
3A5B 
   
4A5B 
 
  
 
 
2A6B 
   
Frazier 51 
3A’6B 
 
  
3A6B 
 
  
5A6B 
  
 
 
TABLE 9. Post-chalcone diffusion photographs of S. enteritidis grown on LB agar after 24-
36-hour incubation at 37° C  
CHALCONE  PLATE 1 PLATE 2 PLATE 3 
2A1B 
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5A1B 
  
 
3A2B 
   
4A2B 
  
 
5A2B 
   
1A3B 
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4A3B 
   
5A3B 
   
1A4B 
   
2A4B 
 
 
 
4A4B 
   
Frazier 54 
5A4B 
   
2A5B 
   
3A’5B 
   
3A5B 
  
 
4A5B 
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2A6B 
 
  
3A’6B 
 
  
3A6B 
  
 
5A6B 
  
 
 
TABLE 10. Post-chalcone diffusion photographs of B. subtilis grown on LB agar after 24-
36-hour incubation at 30° C  
CHALCONE PLATE 1 PLATE 2 PLATE 3 
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2A1B 
   
5A1B 
   
3A2B 
   
4A2B 
   
5A2B 
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1A3B 
   
4A3B 
   
5A3B 
   
1A4B 
   
2A4B 
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4A4B 
  
 
5A4B 
 
 
 
2A5B 
   
3A’5B 
 
 
 
3A5B 
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4A5B 
  
 
2A6B 
 
  
3A’6B 
   
3A6B 
   
5A6B 
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TABLE 11. Post-chalcone diffusion photographs of E. coli grown on LB agar after 24-36-
hour incubation at 37° C  
CHALCONE PLATE 1 PLATE 2 PLATE 3 
2A1B 
   
5A1B 
  
 
3A2B 
   
4A2B 
   
5A2B 
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1A3B 
  
 
4A3B 
   
5A3B 
   
1A4B 
   
2A4B 
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4A4B 
   
5A4B 
   
2A5B 
 
  
3A’5B 
 
 
 
3A5B 
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4A5B 
   
2A6B 
   
3A’6B 
 
 
 
3A6B 
   
5A6B 
   
 
